

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/06848

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/495 A61K31/4188 A61K31/17 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, MEDLINE, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MA JIANGUO ET AL: "Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470" CANCER RESEARCH, vol. 61, no. 14, 15 July 2001 (2001-07-15), pages 5491-5498, XP002258075 ISSN: 0008-5472 abstract page 5497, left-hand column, paragraph 2 -page 5498, left-hand column, paragraph 1</p> <p style="text-align: center;">--- -/--</p>	<p>1,2,5-8, 12,13</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

20 October 2003

Date of mailing of the international search report

05/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06848

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BROWDER T ET AL: "ANTIANGIOGENIC SCHEDULING OF CHEMOTHERAPY IMPROVES EFFICACY AGAINST EXPERIMENTAL DRUG-RESISTANT CANCER"</p> <p>CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 7, 1 April 2000 (2000-04-01), pages 1878-1886, XP001026181</p> <p>ISSN: 0008-5472</p> <p>abstract</p>	1,5-8, 12,13
X	<p>NEWTON H B: "NOVEL CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF BRAIN CANCER"</p> <p>EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 12, 2000, pages 2815-2829, XP001058143</p> <p>ISSN: 1354-3784</p> <p>page 2819, left-hand column, paragraph 2</p>	1,2,5-9, 12,13
X	<p>MEHTA M ET AL: "Brain tumor committee"</p> <p>INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 51, no. 3, 2001, pages 11-18, XP002197215</p> <p>ISSN: 0360-3016</p> <p>page 13, right-hand column, paragraphs 4,5</p> <p>page 15, left-hand column, paragraph 3</p> <p>page 16, left-hand column, paragraph 5</p>	1,2,5-9, 12,13
Y	<p>US 6 258 812 B1 (TRAXLER PETER ET AL)</p> <p>10 July 2001 (2001-07-10)</p> <p>column 2, line 5</p> <p>column 10, line 62 -column 11, line 22</p>	1-13
Y	<p>ROSEN L S: "Angiogenesis inhibition in solid tumors."</p> <p>CANCER JOURNAL (SUDBURY, MASS.) UNITED STATES 2001 NOV-DEC, vol. 7 Suppl 3, November 2001 (2001-11), pages S120-S128, XP009019149</p> <p>ISSN: 1528-9117</p> <p>abstract</p> <p>page 126, left-hand column, line 3-23</p>	1-13
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06848

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KATO TETSURO ET AL: "Enhanced suppression to tumor growth by combination of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice" CANCER RESEARCH, vol. 54, no. 19, 1994, pages 5143-5147, XP001155647 ISSN: 0008-5472 abstract	1-13
Y	TEICHER B A ET AL: "COMPARISON OF SEVERAL ANTIANGIOGENIC REGIMENS ALONE AND WITH CYTOTOXIC THERAPIES IN THE LEWIS LUNG CARCINOMA" CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 38, no. 2, 1996, pages 169-177, XP000973352 ISSN: 0344-5704 abstract	1-13
Y	BOCCI G ET AL: "Antitumor activity of SU5416 in association with gemcitabine in vitro and in mice bearing MIA PaCa-2 human pancreas adenocarcinoma" PANCREAS, vol. 21, no. 4, November 2000 (2000-11), page 432 XP009019148 The Joint Meeting of the American Pancreatic Association and International Association of Pancreatol; Chicago, Illinois, USA; November 01-05, 2000 ISSN: 0885-3177 the whole document	1-13
X,P	WO 02 090346 A (NOVARTIS ERFIND VERWALT GMBH ;MANLEY PAUL WILLIAM (CH); NOVARTIS A) 14 November 2002 (2002-11-14) page 20 -page 21, paragraph 1	1,3,5-8, 10-13
X,P	WO 03 031440 A (SCHERING CORP ;PHARMACOPEIA INC (US)) 17 April 2003 (2003-04-17) page 59 -page 60 claims 47-50	1,3,5-8, 10-13
X,P	WO 02 076926 A (SCHERING CORP ;PHARMACOPEIA INC (US)) 3 October 2002 (2002-10-03) page 22, line 30 -page 24, line 5 claims 26-38	1-13
-/--		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06848

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	<p>LIN BORIS ET AL: "The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment" CANCER RESEARCH, vol. 62, no. 17, 1 September 2002 (2002-09-01), pages 5019-5026, XP002258076 ISSN: 0008-5472 the whole document</p>	1-13

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 1 relates to a compound defined by reference to a desirable characteristic or property, namely vasculostatic compound.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in claims 3-4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/06848

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 7-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06848

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6258812	B1	10-07-2001	AU 731852 B2	05-04-2001
			AU 6621898 A	08-09-1998
			BR 9807685 A	21-03-2000
			CN 1251097 T	19-04-2000
			CZ 9902853 A3	17-11-1999
			WO 9835958 A1	20-08-1998
			EP 0970070 A1	12-01-2000
			HU 0001046 A2	28-04-2001
			JP 2001508800 T	03-07-2001
			NO 993888 A	11-10-1999
			NZ 337064 A	27-04-2001
			PL 335113 A1	10-04-2000
			SK 109699 A3	13-03-2000
			TR 9901953 T2	21-10-1999
			US 2003191129 A1	09-10-2003
			US 2002091261 A1	11-07-2002
			ZA 9801155 A	13-08-1998
WO 02090346	A	14-11-2002	WO 02090346 A1	14-11-2002
WO 03031440	A	17-04-2003	WO 03031440 A1	17-04-2003
WO 02076926	A	03-10-2002	WO 02076926 A1	03-10-2002
			US 2003097004 A1	22-05-2003